A detailed history of Trilogy Capital Inc. transactions in Abb Vie Inc. stock. As of the latest transaction made, Trilogy Capital Inc. holds 4,543 shares of ABBV stock, worth $773,900. This represents 0.05% of its overall portfolio holdings.

Number of Shares
4,543
Previous 4,694 3.22%
Holding current value
$773,900
Previous $805,000 11.43%
% of portfolio
0.05%
Previous 0.04%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024

SELL
$163.84 - $199.33 $24,739 - $30,098
-151 Reduced 3.22%
4,543 $897,000
Q2 2024

Jul 22, 2024

SELL
$154.79 - $180.76 $11,299 - $13,195
-73 Reduced 1.53%
4,694 $805,000
Q1 2024

Apr 17, 2024

SELL
$159.82 - $182.1 $2.38 Million - $2.71 Million
-14,901 Reduced 75.76%
4,767 $868,000
Q4 2023

Jan 11, 2024

SELL
$137.6 - $154.97 $26,694 - $30,064
-194 Reduced 0.98%
19,668 $3.05 Million
Q3 2023

Oct 16, 2023

BUY
$133.59 - $154.65 $15,630 - $18,094
117 Added 0.59%
19,862 $2.96 Million
Q2 2023

Jul 24, 2023

BUY
$132.51 - $164.9 $100,840 - $125,488
761 Added 4.01%
19,745 $2.66 Million
Q1 2023

Apr 17, 2023

BUY
$144.61 - $166.54 $442,217 - $509,279
3,058 Added 19.2%
18,984 $3.03 Million
Q4 2022

Feb 09, 2023

BUY
$138.31 - $165.87 $316,591 - $379,676
2,289 Added 16.79%
15,926 $2.58 Million
Q3 2022

Oct 21, 2022

BUY
$134.21 - $153.93 $217,151 - $249,058
1,618 Added 13.46%
13,637 $1.83 Million
Q2 2022

Jul 20, 2022

SELL
$137.62 - $174.96 $63,305 - $80,481
-460 Reduced 3.69%
12,019 $1.84 Million
Q1 2022

Apr 08, 2022

BUY
$131.98 - $163.75 $249,442 - $309,487
1,890 Added 17.85%
12,479 $2.02 Million
Q4 2021

Jan 18, 2022

BUY
$107.43 - $135.93 $48,665 - $61,576
453 Added 4.47%
10,589 $1.43 Million
Q3 2021

Oct 15, 2021

BUY
$106.4 - $120.78 $3,085 - $3,502
29 Added 0.29%
10,136 $1.09 Million
Q2 2021

Jul 14, 2021

BUY
$105.21 - $117.21 $240,930 - $268,410
2,290 Added 29.3%
10,107 $1.19 Million
Q1 2021

Apr 12, 2021

BUY
$102.3 - $112.62 $128,898 - $141,901
1,260 Added 19.22%
7,817 $846,000
Q4 2020

Feb 05, 2021

BUY
$80.49 - $108.67 $6,680 - $9,019
83 Added 1.28%
6,557 $703,000
Q3 2020

Nov 16, 2020

SELL
$85.91 - $100.83 $30,927 - $36,298
-360 Reduced 5.27%
6,474 $567,000
Q2 2020

Jul 22, 2020

SELL
$73.37 - $98.18 $12,546 - $16,788
-171 Reduced 2.44%
6,834 $680,000
Q1 2020

Apr 28, 2020

SELL
$64.5 - $97.79 $113,907 - $172,697
-1,766 Reduced 20.13%
7,005 $593,000
Q4 2019

Jan 10, 2020

BUY
$72.13 - $90.25 $41,258 - $51,623
572 Added 6.98%
8,771 $780,000
Q3 2019

Oct 07, 2019

BUY
$62.98 - $75.72 $60,964 - $73,296
968 Added 13.39%
8,199 $612,000
Q2 2019

Jul 11, 2019

BUY
$65.7 - $83.98 $45,858 - $58,618
698 Added 10.68%
7,231 $518,000
Q1 2019

Apr 17, 2019

BUY
$77.14 - $90.79 $503,955 - $593,131
6,533 New
6,533 $526,000
Q4 2018

Jan 15, 2019

SELL
$77.85 - $96.01 $17,438 - $21,506
-224 Closed
0 $0
Q3 2018

Oct 31, 2018

BUY
$88.91 - $98.84 $88 - $98
1 Added 0.45%
224 $21,000
Q2 2018

Aug 20, 2018

SELL
$89.78 - $106.23 $359 - $424
-4 Reduced 1.76%
223 $21,000
Q1 2018

May 24, 2018

SELL
$92.01 - $123.21 $729,915 - $977,424
-7,933 Reduced 97.22%
227 $21,000
Q4 2017

Feb 07, 2018

BUY
$89.56 - $98.21 $730,809 - $801,393
8,160
8,160 $789,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $301B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Trilogy Capital Inc. Portfolio

Follow Trilogy Capital Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Trilogy Capital Inc., based on Form 13F filings with the SEC.

News

Stay updated on Trilogy Capital Inc. with notifications on news.